David S. McClintock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David S. McClintock has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Steven N. Hart
Department of Laboratory Medicine and Pathology, Division of Computational Pathology and Informatics, Mayo Clinic , Rochester, MN
4 shared publications Christopher A Garcia
Department of Laboratory Medicine and Pathology, Division of Computational Pathology and Informatics, Mayo Clinic , Rochester, MN
3 shared publicationsDebra A Novak
Department of Laboratory Medicine and Pathology, Division of Computational Pathology and Informatics, Mayo Clinic , Rochester, MN
2 shared publicationsEric Lantz
Department of Laboratory Medicine and Pathology, Division of Computational Pathology and Informatics, Mayo Clinic , Rochester, MN
2 shared publicationsKatelyn A Reed
Department of Laboratory Medicine and Pathology, Division of Computational Pathology and Informatics, Mayo Clinic , Rochester, MN
2 shared publications- Mark D. Zarella
Department of Laboratory Medicine and Pathology, Division of Computational Pathology and Informatics, Mayo Clinic , Rochester, MN
2 shared publications
Latest Publications
- 5 May 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (5)
The CARE framework for AI dataset documentation in clinical laboratories: a comprehensive checklist and data lineage methodology
Objectives: Traditional laboratory regulatory frameworks provide robust guidance for conventional clinical testing but lack requirements for data documentation for artificial intelligence and machine learning (AI/ML) solutions. This gap creates significant risks since AI solutions directly inherit patterns, biases, and limitations from their training data. Here, we describe the development and implementation of a comprehensive data documentation checklist with accompanying data lineage for use within an AI lifecycle framework for clinical laboratories. Methods: Building on the previously established Clinical AI Readiness Evaluator (CARE) framework, we developed a comprehensive data checklist and data lineage methodology through a multiphase process, including (1) comprehensive review of existing AI/ML data documentation frameworks, (2) focused meetings with 3 institutional AI operations teams, and (3) 3 rounds of iterative refinement by our multidisciplinary team. The checklist’s effectiveness was then assessed using 3 diverse AI/ML projects moving through the CARE framework. Results: The CARE Data Checklist and Data Lineage provide a structured approach to documenting critical aspects of datasets used in AI/ML projects, including data composition, demographics, collection methods, labeling processes, usage constraints, maintenance requirements, and a data readiness assessment. The checklist addresses unique data-centric challenges of AI/ML applications, facilitating transparency, reproducibility, and regulatory compliance. Conclusions: The CARE Data Checklist and Data Lineage serve as both a technical guide and a communication tool bridging gaps between technical and clinical stakeholders. By working on these documents early in the AI lifecycle, laboratories can anticipate and address data-related challenges, ultimately saving time, optimizing resources, and improving the reliability of AI-augmented laboratory solutions.
- 5 May 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (5)
The CARE framework for AI dataset documentation in clinical laboratories: a comprehensive checklist and data lineage methodology
Objectives: Traditional laboratory regulatory frameworks provide robust guidance for conventional clinical testing but lack requirements for data documentation for artificial intelligence and machine learning (AI/ML) solutions. This gap creates significant risks since AI solutions directly inherit patterns, biases, and limitations from their training data. Here, we describe the development and implementation of a comprehensive data documentation checklist with accompanying data lineage for use within an AI lifecycle framework for clinical laboratories. Methods: Building on the previously established Clinical AI Readiness Evaluator (CARE) framework, we developed a comprehensive data checklist and data lineage methodology through a multiphase process, including (1) comprehensive review of existing AI/ML data documentation frameworks, (2) focused meetings with 3 institutional AI operations teams, and (3) 3 rounds of iterative refinement by our multidisciplinary team. The checklist’s effectiveness was then assessed using 3 diverse AI/ML projects moving through the CARE framework. Results: The CARE Data Checklist and Data Lineage provide a structured approach to documenting critical aspects of datasets used in AI/ML projects, including data composition, demographics, collection methods, labeling processes, usage constraints, maintenance requirements, and a data readiness assessment. The checklist addresses unique data-centric challenges of AI/ML applications, facilitating transparency, reproducibility, and regulatory compliance. Conclusions: The CARE Data Checklist and Data Lineage serve as both a technical guide and a communication tool bridging gaps between technical and clinical stakeholders. By working on these documents early in the AI lifecycle, laboratories can anticipate and address data-related challenges, ultimately saving time, optimizing resources, and improving the reliability of AI-augmented laboratory solutions.
- 12 July 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
Establishing a comprehensive artificial intelligence lifecycle framework for laboratory medicine and pathology: A series introduction
Objective: Despite exponential growth in artificial intelligence (AI) research for laboratory medicine and pathology, a significant gap exists between model development and clinical AI implementation. This article introduces a structured framework, the Clinical AI Readiness Evaluator (CARE), to bridge this gap and support the responsible adoption of AI in clinical laboratory settings. Methods: Building upon the Machine Learning Technology Readiness Levels framework, we developed CARE specifically for the clinical laboratory environment by incorporating health care–specific requirements, regulatory considerations, and workflow integration needs. This framework was iteratively refined through practical application across diverse AI use cases within laboratory medicine and pathology. Results: The CARE framework provides a systematic approach to AI development and implementation through 8 component workstreams: clinical use case, data, data pipeline, code, clinical user experience, clinical technology infrastructure, clinical orchestration, and regulatory compliance. Unlike generic AI frameworks, CARE distinguishes itself by emphasizing both health care and laboratory workflow integration, regulatory requirements, ethical considerations, and comprehensive validation for clinical contexts. The framework accommodates both internally developed models and commercial AI solutions, providing clear guidance through technology readiness levels and structured review processes. Conclusions: The CARE framework addresses the unique challenges of implementing AI in laboratory medicine and pathology by providing a comprehensive roadmap from initial concepts through clinical deployment and maintenance. This article, the first in a series of 4, establishes the foundational AI lifecycle framework, while subsequent articles will explore data documentation, ethical AI considerations, and governance structures. By adopting this structured approach, laboratories can responsibly harness AI’s potential to enhance diagnostic accuracy and operational efficiencies and, ultimately, improve patient care.
- 12 July 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
Establishing a comprehensive artificial intelligence lifecycle framework for laboratory medicine and pathology: A series introduction
Objective: Despite exponential growth in artificial intelligence (AI) research for laboratory medicine and pathology, a significant gap exists between model development and clinical AI implementation. This article introduces a structured framework, the Clinical AI Readiness Evaluator (CARE), to bridge this gap and support the responsible adoption of AI in clinical laboratory settings. Methods: Building upon the Machine Learning Technology Readiness Levels framework, we developed CARE specifically for the clinical laboratory environment by incorporating health care–specific requirements, regulatory considerations, and workflow integration needs. This framework was iteratively refined through practical application across diverse AI use cases within laboratory medicine and pathology. Results: The CARE framework provides a systematic approach to AI development and implementation through 8 component workstreams: clinical use case, data, data pipeline, code, clinical user experience, clinical technology infrastructure, clinical orchestration, and regulatory compliance. Unlike generic AI frameworks, CARE distinguishes itself by emphasizing both health care and laboratory workflow integration, regulatory requirements, ethical considerations, and comprehensive validation for clinical contexts. The framework accommodates both internally developed models and commercial AI solutions, providing clear guidance through technology readiness levels and structured review processes. Conclusions: The CARE framework addresses the unique challenges of implementing AI in laboratory medicine and pathology by providing a comprehensive roadmap from initial concepts through clinical deployment and maintenance. This article, the first in a series of 4, establishes the foundational AI lifecycle framework, while subsequent articles will explore data documentation, ethical AI considerations, and governance structures. By adopting this structured approach, laboratories can responsibly harness AI’s potential to enhance diagnostic accuracy and operational efficiencies and, ultimately, improve patient care.
- Open Access
- 6 September 2024
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 2 (4) , 574-583
Embedding Internal Accountability Into Health Care Institutions for Safe, Effective, and Ethical Implementation of Artificial Intelligence Into Medical Practice: A Mayo Clinic Case Study
- 6 September 2024
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 2 (4) , 574-583
Open AccessEmbedding Internal Accountability Into Health Care Institutions for Safe, Effective, and Ethical Implementation of Artificial Intelligence Into Medical Practice: A Mayo Clinic Case Study
- Open Access
- 1 October 2023
- Published by Elsevier in Journal of Pathology Informatics
- Vol. 14, 100338
Organizational preparedness for the use of large language models in pathology informatics
- 1 October 2023
- Published by Elsevier in Journal of Pathology Informatics
- Vol. 14, 100338
Open AccessOrganizational preparedness for the use of large language models in pathology informatics
- Open Access
- 31 July 2023
- Published by SPIE-Intl Soc Optical Eng in Journal of Medical Imaging
- Vol. 10 (05) , 051802-12
Artificial intelligence and digital pathology: clinical promise and deployment considerations
Digital pathology (DP) is a blanket term encompassing the tools, systems, enabling infrastructure, and associated metadata used when digitizing pathology slides into whole-slide images (WSIs).1,2 Over the last 20 years, technology has advanced to the point at which WSIs (often gigabytes in size) can be captured in minutes and presented to a pathologist for multiple purposes, such as telepathology, research, education, and primary diagnosis (i.e., digital signout). Digitization has many potential benefits, both for pathology laboratories and patients, by introducing efficiencies in distribution/sharing, recall, and reuse of pathology assets. It also provides the required substrate for digital image analysis of histopathology. Although image analysis of WSIs is not new and has been in use for well over ten years,3 recent advances in machine learning and computing have greatly expanded image analysis performance and capabilities. Linking image analysis with other clinical data and concepts is termed “computational pathology” and has become heavily dependent on the use of artificial intelligence (AI), expanding the potential for dramatic improvements in pathology automation, diagnostic accuracy, and treatment guidance.1,4,5
- 31 July 2023
- Published by SPIE-Intl Soc Optical Eng in Journal of Medical Imaging
- Vol. 10 (05) , 051802-12
Open AccessArtificial intelligence and digital pathology: clinical promise and deployment considerations
Digital pathology (DP) is a blanket term encompassing the tools, systems, enabling infrastructure, and associated metadata used when digitizing pathology slides into whole-slide images (WSIs).1,2 Over the last 20 years, technology has advanced to the point at which WSIs (often gigabytes in size) can be captured in minutes and presented to a pathologist for multiple purposes, such as telepathology, research, education, and primary diagnosis (i.e., digital signout). Digitization has many potential benefits, both for pathology laboratories and patients, by introducing efficiencies in distribution/sharing, recall, and reuse of pathology assets. It also provides the required substrate for digital image analysis of histopathology. Although image analysis of WSIs is not new and has been in use for well over ten years,3 recent advances in machine learning and computing have greatly expanded image analysis performance and capabilities. Linking image analysis with other clinical data and concepts is termed “computational pathology” and has become heavily dependent on the use of artificial intelligence (AI), expanding the potential for dramatic improvements in pathology automation, diagnostic accuracy, and treatment guidance.1,4,5
- Open Access
- 1 July 2023
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 8, 22
A clinical laboratorian’s journey in developing a machine learning algorithm to assist in testing utilization and stewardship
Background: Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy (TMA) and a medical emergency. The ADAMTS13 (AS13) activity assay is needed to confirm the diagnosis. Within the context of limited laboratory resources, a machine learning (ML) was developed to potentially reduce overutilization of AS13 testing and aid clinical colleagues in the future. Methods: A hybrid approach, consisting of both inhouse and literature data, was taken to acquire the data to train and test the decision tree (DT) ML model. The dataset consisted of 104 patients (30 inhouse, 74 literature-derived) with an equal mix of TTP to non-TTP patients (52 each). The features used to develop the supervised DT model were directly acquired from the PLASMIC score. Results: The optimized DT model overall accuracy on the testing dataset was 81%. The sensitivity, specificity, positive and negative predictive were 100%, 69%, 67%, and 100%, respectively. Conclusions: We were able to improve the overall performance of the DT model while maintaining a high NPV. However, this invariably translated to potentially increased false positive results (outcomes classified as TTP are actually non-TTP), our overall goal was not to restrict testing on any potentially true TTP cases. This study was done with limited clinical laboratory resources and continues to be a project in progress. However, as laboratory specialists become more involved in artificial intelligence (AI)/ML initiatives, institutions will need to provide them with a modern information technology (IT) infrastructure with adequate resources to enable these efforts to meet the needs of the future health care system.
- 1 July 2023
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 8, 22
Open AccessA clinical laboratorian’s journey in developing a machine learning algorithm to assist in testing utilization and stewardship
Background: Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy (TMA) and a medical emergency. The ADAMTS13 (AS13) activity assay is needed to confirm the diagnosis. Within the context of limited laboratory resources, a machine learning (ML) was developed to potentially reduce overutilization of AS13 testing and aid clinical colleagues in the future. Methods: A hybrid approach, consisting of both inhouse and literature data, was taken to acquire the data to train and test the decision tree (DT) ML model. The dataset consisted of 104 patients (30 inhouse, 74 literature-derived) with an equal mix of TTP to non-TTP patients (52 each). The features used to develop the supervised DT model were directly acquired from the PLASMIC score. Results: The optimized DT model overall accuracy on the testing dataset was 81%. The sensitivity, specificity, positive and negative predictive were 100%, 69%, 67%, and 100%, respectively. Conclusions: We were able to improve the overall performance of the DT model while maintaining a high NPV. However, this invariably translated to potentially increased false positive results (outcomes classified as TTP are actually non-TTP), our overall goal was not to restrict testing on any potentially true TTP cases. This study was done with limited clinical laboratory resources and continues to be a project in progress. However, as laboratory specialists become more involved in artificial intelligence (AI)/ML initiatives, institutions will need to provide them with a modern information technology (IT) infrastructure with adequate resources to enable these efforts to meet the needs of the future health care system.
- 4 January 2023
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (1) , 226-228
The Roadmap to Interoperability and Laboratory Data: Current State and Next Steps
- 4 January 2023
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (1) , 226-228
The Roadmap to Interoperability and Laboratory Data: Current State and Next Steps
- Open Access
- 4 January 2023
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (1) , 145-161
Cybersecurity and Information Assurance for the Clinical Laboratory
Background: Network-connected medical devices have rapidly proliferated in the wake of recent global catalysts, leaving clinical laboratories and healthcare organizations vulnerable to malicious actors seeking to ransom sensitive healthcare information. As organizations become increasingly dependent on integrated systems and data-driven patient care operations, a sudden cyberattack and the associated downtime can have a devastating impact on patient care and the institution as a whole. Cybersecurity, information security, and information assurance principles are, therefore, vital for clinical laboratories to fully prepare for what has now become inevitable, future cyberattacks. Content: This review aims to provide a basic understanding of cybersecurity, information security, and information assurance principles as they relate to healthcare and the clinical laboratories. Common cybersecurity risks and threats are defined in addition to current proactive and reactive cybersecurity controls. Information assurance strategies are reviewed, including traditional castle-and-moat and zero-trust security models. Finally, ways in which clinical laboratories can prepare for an eventual cyberattack with extended downtime are discussed. Summary: The future of healthcare is intimately tied to technology, interoperability, and data to deliver the highest quality of patient care. Understanding cybersecurity and information assurance is just the first preparative step for clinical laboratories as they ensure the protection of patient data and the continuity of their operations.
- 4 January 2023
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (1) , 145-161
Open AccessCybersecurity and Information Assurance for the Clinical Laboratory
Background: Network-connected medical devices have rapidly proliferated in the wake of recent global catalysts, leaving clinical laboratories and healthcare organizations vulnerable to malicious actors seeking to ransom sensitive healthcare information. As organizations become increasingly dependent on integrated systems and data-driven patient care operations, a sudden cyberattack and the associated downtime can have a devastating impact on patient care and the institution as a whole. Cybersecurity, information security, and information assurance principles are, therefore, vital for clinical laboratories to fully prepare for what has now become inevitable, future cyberattacks. Content: This review aims to provide a basic understanding of cybersecurity, information security, and information assurance principles as they relate to healthcare and the clinical laboratories. Common cybersecurity risks and threats are defined in addition to current proactive and reactive cybersecurity controls. Information assurance strategies are reviewed, including traditional castle-and-moat and zero-trust security models. Finally, ways in which clinical laboratories can prepare for an eventual cyberattack with extended downtime are discussed. Summary: The future of healthcare is intimately tied to technology, interoperability, and data to deliver the highest quality of patient care. Understanding cybersecurity and information assurance is just the first preparative step for clinical laboratories as they ensure the protection of patient data and the continuity of their operations.
- Top Cited PapersOpen Access
- 4 January 2023
- Published by Elsevier in EBioMedicine
- Vol. 88, 104427
Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade
- 4 January 2023
- Published by Elsevier in EBioMedicine
- Vol. 88, 104427
Top Cited PapersOpen AccessComputational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade